Lung cancer patients with previous or simultaneous urologic cancers

Miyazaki, Kunihiko; Satoh, Hiroaki; Kagohashi, Katsunori; Kurishima, Koichi; Ishikawa, Hiroichi; Ohtsuka, Morio; Sekizawa, Kiyohisa

doi:10.1007/s12032-008-9063-1

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This phenomenon has been previously reported [8,9,15–18] and an increase in the prevalence of patients with two or more primary tumours has been documented in recent decades [6,7,10]. The risk of lung cancer as a second neoplasia in patients with NMIBC in the present study is remarkable and higher than that in previous reports [8–10,16,18].…”

Section: Discussionsupporting

confidence: 73%

“…Epidemiological studies have shown that after 8 years, patients with NMIBC have an increased risk of a second neoplasm [6,7]. An increased relative risk of lung cancer among patients with NMIBC has also been reported [8–10]. There have been very few studies in Spain on the quantification of the risk of developing a second primary neoplasm after having NMIBC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Are patients with non‐muscle‐invasive bladder cancer a suitable population for a lung cancer screening trial?

et al. 2010

View full text Add to dashboard Cite

Study Type – Prognosis (case series) Level of Evidence 4 OBJECTIVE To estimate the relative risk of developing a second primary neoplasm, in particular lung cancer, after having non‐muscle‐invasive bladder cancer (NMIBC). PATIENTS AND METHODS Patients were included in the study if they had developed NMIBC between 1995 and 2003. All clinical data were extracted from the medical records of our institution’s database. The interval between neoplasms, smoking habits, histological subtypes and survival were also analysed. Patient follow‐up was ≥5 years. RESULTS We found 231 patients with NMIBC, 39 of which had a second primary neoplasm: 10 lung cancer, one pancreas, one gastric, one pharynx, one liver, one parathyroid, one oesophageal, five basal cell carcinoma, three larynx, two colon, three rectal and 10 prostate. In patients with lung cancer, NMIBC was the first primary tumour. Overall, the median (range) interval between occurrence of NMIBC and lung cancer was 54.2 (8–168) months. For the relationship between the observed and expected cases of lung cancer, after normalizing our frequencies to the sex ratio and age of our group of patients, the risk of lung cancer was 10.27‐fold higher in patients with NMIBC as compared with the general population of Catalonia (95% confidence interval 4.92–18.88). CONCLUSION We consider that an annual examination for the detection and prevention of lung cancer must be included in clinical guides for patients with NMIBC. This proposal is reinforced by the finding that death in our group of patients with both tumours was always derived from lung cancer and not from bladder cancer.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Are patients with non‐muscle‐invasive bladder cancer a suitable population for a lung cancer screening trial?

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The risk of developing NSCLC is reportedly increased in bladder cancer patients but is incompletely described in patients with other urologic malignancies such as prostate or renal cancers 11, 12 and in those with previous cervical cancer 13, 14 . Research on breast cancer survivors that develop NSCLC is more abundant; however, the extent to which prior breast cancer confers increased risk for NSCLC independent of age, smoking, and radiation therapy remains unclear 15-21 .…”

Section: Introductionmentioning

confidence: 99%

Non–Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?

Nelson

Kim

et al. 2017

Clinical Lung Cancer

View full text Add to dashboard Cite

Background Patients with prior malignancies may be at increased risk for non-small cell lung cancer (NSCLC). However, the extent of risk is unknown for many cancer types and it is unclear who may benefit from screening. Methods The Surveillance, Epidemiology and End Results dataset from 1992-2012 was used to identify patients with prior malignancies who were diagnosed with NSCLC ≥6 months after their initial cancer. Standardized incidence ratios (SIR) for NSCLC were calculated as a ratio of observed to expected cases adjusted by person-years at risk. Cancers with SIR >1.0 had higher risk for NSCLC than expected. Analyses were stratified by sex, radiation, and histology. Results Among cancer survivors, 32,058 developed NSCLC. Smoking-related (lung, head and neck, bladder) and hematologic malignancies regardless of prior radiation therapy had the highest SIR for NSCLC (range 1.97-4.88). Prior colorectal and renal cancer survivors also had increased SIR for NSCLC (1.16 and 1.21, respectively). Women with previous pancreatic cancer treated with radiation, breast cancer with or without radiation, and those with thyroid cancer demonstrated higher SIR for lung adenocarcinoma. Men with prior irradiated prostate cancer also had elevated SIR (1.08, CI 1.01-1.15) for lung adenocarcinoma. Patients with melanoma, prostate or uterine cancer had lower SIR for NSCLC than expected. Conclusions Smoking-related malignancies had the highest risk for NSCLC. Radiation conferred elevated risk for NSCLC for certain cancers. Melanoma, prostate, uterine cancer survivors were at low risk for NSCLC. These results may help identify high-risk screening candidates in the growing population of cancer survivors.

show abstract

“…In a retrospective study including 1105 lung cancer patients, 13 patients had urologic malignancies, 11 were tobacco related, and 12 of them died due to lung cancer, while relapse of urologic malignancies was not seen during follow up of patients. Median survival of NSCLC patients was 18 months [13]. Because our patient was 67 years old and a smoker, there was an increased risk of MIP.…”

Section: Discussionmentioning

confidence: 95%

False Positivity and False Negativity on Positron Emission Tomography in a Patient with Lung Cancer

Akpınar¹,

Haliloğlu²,

Öztürk³

et al. 2013

Tur Toraks Der

View full text Add to dashboard Cite

Lung cancer patients with previous or simultaneous urologic cancers

Abstract: For patients with urological cancers, smoking cessation, a chest radiograph or CT scan at least yearly and swift evaluation of signs or symptoms that are suggestive of lung cancer should be recommended.

Cited by 4 publications

References 18 publications

Are patients with non‐muscle‐invasive bladder cancer a suitable population for a lung cancer screening trial?

Are patients with non‐muscle‐invasive bladder cancer a suitable population for a lung cancer screening trial?

Non–Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?

False Positivity and False Negativity on Positron Emission Tomography in a Patient with Lung Cancer

Contact Info

Product

Resources

About